SIRPA and acute myeloid leukemia: To determine the specificity of MSLN targeting, we also evaluated the binding (Supplementary Figure S3d) and blocking capacity (Supplementary Figure S3e) of the SIRPα–αMSLN4D8 LicMAb to the MSLNneg/CD33pos AML cell line MOLM-13.